{"ATC Code":"A - Alimentary tract and metabolism","Abbreviation":"","Aliases":["19-Nortestosterone","19-Norandrostenolone","Norandrostenolone","Nortestosterone","Menidrabol","Nandrolon","Nortestonate","Oestrenolon","Norandrostenolon","17β-Hydroxy-4-estren-3-one"],"CAS":"434-22-0","ChEBI":"CHEBI:7466","ChEMBL":"CHEMBL757","ChemicalClasses":["steroid"],"Chirality":"absolute","Color/Form":"Dimorphic crystals","Dosing Info":[],"Drug Warnings":"Use of anabolic steroids by athletes is not recommended. Objective evidence is conflicting and inconclusive as to whether these medications significantly increase athletic performance by increasing muscle strength. Weight gains reported by athletes are due in part to fluid retention, which is a potentially hazardous side effect of anabolic steroid therapy. The risk of other unwanted effects, such as testicular atrophy and suppression of spermatogenesis in males; menstrual disturbances and virilization, such as deepening of voice, development of acne, and unnatural growth of body hair in females; peliosis hepatis or other hepatotoxicity; and hepatic cancer outweigh and possible benefit received from anabolic steroids and make their use in athletes inappropriate. /Anabolic steroids/","DrugClasses":[],"DurationOfAction":"• Nandrolone decanoate (Intramuscular injection): 2–3 weeks • Nandrolone phenylpropionate (Intramuscular injection): 5–7 days","EINECS":"207-101-0","EliminationHalfLife":"• Nandrolone: \u003c4.3 hours • Nandrolone decanoate (Intramuscular injection): 6–12 days • Nandrolone phenylpropionate: 2.7 days","Esters":["acetate","benzoate","cypionate","undecylate","propionate"],"European Community (EC) Number":"207-101-0","FDA Pharmacological Classification":"6PG9VR430D","HMDB ID":"HMDB0002725","HeavyAtomCount":20,"IUPACName":"(8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one","InChI":"InChI=1S/C18H26O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-17,20H,2-9H2,1H3/t13-,14+,15+,16-,17-,18-/m0/s1","InChIKey":"NPAGDVCDWIYMMC-IZPLOLCNSA-N","MeSH Pharmacological Classification":"Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. (See all compounds classified as Androgens.)","Melting Point":"112 and 124 °C","MolecularFormula":"C\u003csub\u003e18\u003c/sub\u003eH\u003csub\u003e26\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"274.4 g/mol","Opticalactivity":"UNSPECIFIED","Physical Description":"Solid","PrevSalts":[],"PubChemId":9904,"Record Description":["Nandrolone is a 3-oxo Delta(4)-steroid that is estr-4-en-3-one substituted by a beta-hydroxy group at position 17. It has a role as a human metabolite. It is a 17beta-hydroxy steroid, a 3-oxo-Delta(4) steroid and an anabolic androgenic steroid. It derives from a hydride of an estrane.","Nandrolone, also known as 19-nortestosterone or 19-norandrostenolone, is a synthetic anabolic-androgenic steroid (AAS) derived from testosterone.","Nandrolone is an Androgen.","Nandrolone has been reported in Arabidopsis thaliana with data available.","Nandrolone is a synthetic, anabolic steroid analog of testosterone. Similar to testosterone, nortestosterone (19-Nortestosterone) binds to and activates specific nuclear receptors.  This agent may be used for testosterone replacement therapy in hypogonadal men, in HIV-wasting syndrome, and in other conditions in order to increase nitrogen retention and fat-free muscle mass.","NANDROLONE is a small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.","C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of ESTRADIOL to resemble TESTOSTERONE but less one carbon at the 19 position.","Nandrolone is a 3-oxo Delta(4)-steroid that is estr-4-en-3-one substituted by a beta-hydroxy group at position 17. It has a role as a human metabolite. It is a 17beta-hydroxy steroid, a 3-oxo-Delta(4) steroid and an anabolic androgenic steroid. It derives from a hydride of an estrane.","LiverTox|Endocrine|Hormone replacement|Androgen","Wikipedia|List of designer drugs|Androgens|Estranes"],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Nandrolone","Name":"Nandrolone","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q421709","Name":"Nandrolone","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB13169","Name":"Nandrolone","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/9904","Name":"Nandrolone","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL757","Name":"Nandrolone","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7466","Name":"Nandrolone","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=434-22-0","Name":"Nandrolone","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0002725","Name":"Nandrolone","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07254","Name":"Nandrolone","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/6PG9VR430D","Name":"Nandrolone","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID7023350","Name":"Nandrolone","Sub":false}]}],"SMILES":"C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@H]34","Scheduling":[{"gov":"Brazil","schedule":"C5 substance"},{"gov":"Canada","schedule":"Schedule IV substance"},{"gov":"United Kingdom","schedule":"Class C substance"},{"gov":"United States","schedule":"Schedule III substance"}],"Solubility":"Soluble in ether, chloroform, and alcohol","StoreUNII":["6PG9VR430D"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="64.739mm" version="1.2" viewBox="0 0 116.816 64.739" width="116.816mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#000000" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="65.0" stroke="none" width="117.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <path class="bond" d="M81.606 15.899l.697 .073l3.331 -14.974l-2.089 -.219l-2.089 -.219z" id="mol1bnd1" stroke="none"/>
                  
            <line class="bond" id="mol1bnd2" x1="81.955" x2="68.848" y1="15.936" y2="8.316"/>
                  
            <line class="bond" id="mol1bnd3" x1="68.848" x2="55.64" y1="8.316" y2="15.936"/>
                  
            <line class="bond" id="mol1bnd4" x1="55.64" x2="55.64" y1="15.936" y2="31.176"/>
                  
            <line class="bond" id="mol1bnd5" x1="55.64" x2="68.848" y1="31.176" y2="38.796"/>
                  
            <line class="bond" id="mol1bnd6" x1="68.848" x2="81.955" y1="38.796" y2="31.176"/>
                  
            <line class="bond" id="mol1bnd7" x1="81.955" x2="81.955" y1="15.936" y2="31.176"/>
                  
            <line class="bond" id="mol1bnd8" x1="81.955" x2="96.483" y1="31.176" y2="35.85"/>
                  
            <line class="bond" id="mol1bnd9" x1="96.483" x2="105.424" y1="35.85" y2="23.556"/>
                  
            <line class="bond" id="mol1bnd10" x1="105.424" x2="96.483" y1="23.556" y2="11.161"/>
                  
            <line class="bond" id="mol1bnd11" x1="81.955" x2="96.483" y1="15.936" y2="11.161"/>
                  
            <path class="bond" d="M96.309 10.857l.349 .607l10.581 -4.575l-.831 -1.443l-.831 -1.443z" id="mol1bnd12" stroke="none"/>
                  
            <line class="bond" id="mol1bnd13" x1="68.848" x2="68.848" y1="38.796" y2="54.036"/>
                  
            <line class="bond" id="mol1bnd14" x1="68.848" x2="55.64" y1="54.036" y2="61.656"/>
                  
            <line class="bond" id="mol1bnd15" x1="55.64" x2="42.432" y1="61.656" y2="54.036"/>
                  
            <g class="bond" id="mol1bnd16">
                        
                <line x1="29.224" x2="42.432" y1="61.656" y2="54.036"/>
                        
                <line x1="29.224" x2="39.994" y1="58.841" y2="52.628"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd17" x1="29.224" x2="16.016" y1="61.656" y2="54.036"/>
                  
            <g class="bond" id="mol1bnd18">
                        
                <line x1="17.236" x2="6.707" y1="54.74" y2="60.821"/>
                        
                <line x1="16.016" x2="5.487" y1="52.628" y2="58.709"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="6.707000000000001" x2="11.9715" y1="60.821" y2="57.7805"/>
                <line class="hi" stroke="#FF0D0D" x1="5.487" x2="10.7515" y1="58.709" y2="55.6685"/>
            </g>
                  
            <line class="bond" id="mol1bnd19" x1="16.016" x2="16.016" y1="54.036" y2="38.796"/>
                  
            <line class="bond" id="mol1bnd20" x1="16.016" x2="29.224" y1="38.796" y2="31.176"/>
                  
            <line class="bond" id="mol1bnd21" x1="29.224" x2="42.432" y1="31.176" y2="38.796"/>
                  
            <line class="bond" id="mol1bnd22" x1="55.64" x2="42.432" y1="31.176" y2="38.796"/>
                  
            <line class="bond" id="mol1bnd23" x1="42.432" x2="42.432" y1="54.036" y2="38.796"/>
                  
            <g class="bond" id="mol1bnd24">
                        
                <line x1="55.99" x2="55.29" y1="31.176" y2="31.176"/>
                        
                <line x1="56.282" x2="54.998" y1="33.716" y2="33.716"/>
                        
                <line x1="56.574" x2="54.707" y1="36.256" y2="36.256"/>
                        
                <line x1="56.865" x2="54.415" y1="38.796" y2="38.796"/>
                        
                <line x1="57.157" x2="54.123" y1="41.336" y2="41.336"/>
                      
            </g>
                  
            <path class="bond" d="M68.498 38.796h.7l1.308 -11.39h-1.658h-1.658z" id="mol1bnd25" stroke="none"/>
                  
            <g class="bond" id="mol1bnd26">
                        
                <line x1="82.305" x2="81.605" y1="31.176" y2="31.176"/>
                        
                <line x1="82.596" x2="81.313" y1="33.716" y2="33.716"/>
                        
                <line x1="82.888" x2="81.021" y1="36.256" y2="36.256"/>
                        
                <line x1="83.18" x2="80.729" y1="38.796" y2="38.796"/>
                        
                <line x1="83.471" x2="80.438" y1="41.336" y2="41.336"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm11">
                        
                <path d="M111.95 3.553q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.245 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.733 -.0 1.233 .315q.5 .31 .756 .876q.256 .565 .256 1.327zM108.086 3.553q.0 .923 .387 1.459q.393 .529 1.22 .529q.84 .0 1.221 -.529q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" fill="#FF0D0D" stroke="none"/>
                        
                <path d="M116.256 6.006h-.619v-2.286h-2.512v2.286h-.614v-4.9h.614v2.072h2.512v-2.072h.619v4.9z" fill="#FF0D0D" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M5.078 61.655q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.882q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .876q.256 .565 .256 1.327zM1.215 61.655q-.0 .923 .387 1.459q.393 .529 1.22 .529q.84 .0 1.221 -.529q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" fill="#FF0D0D" id="mol1atm17" stroke="none"/>
                  
            <path class="atom" d="M57.512 48.866h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619v4.9z" id="mol1atm21" stroke="none"/>
                  
            <path class="atom" d="M70.72 26.006h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619v4.9z" id="mol1atm22" stroke="none"/>
                  
            <path class="atom" d="M83.827 48.866h-.619v-2.286h-2.512v2.286h-.614v-4.9h.614v2.072h2.512v-2.072h.619v4.9z" id="mol1atm23" stroke="none"/>
                
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"Anabolic Steroids","Title":"Nandrolone","UNII":"6PG9VR430D","Wikidata":"Q421709","Wikipedia":"Nandrolone","XLogP":2.6}